AbbVie Shares Gain as SKYRIZI Hits Primary Endpoints in Crohn's Study
AbbVie's SKYRIZI achieves significant endoscopic remission in Phase 3 Crohn's disease trials, bolstering the company's immunology portfolio and growth outlook.
AbbVie's SKYRIZI achieves significant endoscopic remission in Phase 3 Crohn's disease trials, bolstering the company's immunology portfolio and growth outlook.
AbbVie's ABBV-295 shows promising Phase 1 results with a long half-life, enabling potential bi-weekly dosing and strengthening the company's metabolic drug pipeline.
Investors are prioritizing clinical-stage biotechs with proven potential, as eight companies navigate the IPO process with varying degrees of market readiness and…
AbbVie launches a $10 billion bond offering to finance the Apogee Therapeutics deal, marking a major pharmaceutical M&A debt issuance in 2026.
AbbVie beat Q2 earnings estimates fueled by Botox demand revival, sending shares higher.
Galderma shares sank after the FDA rejected its Botox rival Relfydess, delaying U.S. market entry and strengthening AbbVie's grip on the aesthetics…